Nonhematologic Cancers. Embolism and thrombosis of unspecified artery
Conditions
Interventions
Intervention 1: Intervention group: Oral rivaroxaban treatment group, 15 mg every 12 hours for the first three weeks and then 20 mg daily / Axabin
Abidi Company, Tehran. Intervention 2: Intervention group: The dose of enoxaparin (Lovenox
Osweh Pharmacy, Tehran) was 1 mg per kg body weight, but because 60 or 80 mg ampoules were used, depending on the patient's weight, 60 or 80 mg of the drug every 12 hours as the following injection It
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Existence of active cancer with Venous thromboembolism The age range is between 18-75 years Tendency to participate in the study
Exclusion criteria
Exclusion criteria: Smoking, alcohol and drug abuse Lack of sufficient and appropriate evidence for the occurrence of early Venous thromboembolism Diagnosis of thrombophilic conditions Prescribe any anticoagulant drug excepting Enoxaparin or Rivaroxaban (for example Heparin, Warfarin, Dabigatran, Apixaban, and Edoxaban)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of VTE (Venous thromboembolism) is deep vein thromboembolism (DVT) or pulmonary embolism (PE) according to the report of CT scan of the pulmonary arteries and color Doppler ultrasound of the lower extremity to be reported by the radiologist. Timepoint: At the beginning of the study (before the intervention) and 6 months later. Method of measurement: according to the report of CT scan of the pulmonary arteries and color Doppler ultrasound of the lower extremity to be reported by the radiologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfrooz Kargaran Dehkordi
Ahvaz University of Medical Sciences
Outcome results
None listed